Lawrence Baum, MD
Urology · Houston, TXNPI 1336375484
Payments from drug & device makers
Across 773 payments — averaging $192.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$116K
- HMU Consumables, LLC$9K
- Boston Scientific$5K
- Medtronic$3K
- Myriad Genetic Laboratories, Inc.$1K
- Endo Pharmaceuticals Inc.$1K
- plus $14K from 54 others
Across 10 payments — averaging $6935.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$69K
What the payments were for
- Travel & lodging$1,5415%
- Food & beverage$25,65979%
- Education$2501%
- Other$5,14316%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$26,786
- INTERSTIM$2,006
- SpaceOAR VUE System - 10mL$740
- ALTIS$542
- XIAFLEX$540
- AMS 700$410
- AMS$331
- Prolaris$321
- SpaceOAR System$280
- CVAC Aspiration System$268
- Axonics$252
- UroLift$251
- HydroPearl$248
- GlideWire$248
- Azur CX Detachable$248
- GENERAL KIDNEY STONE DISEASE$236
- AMS 700 CXR RTE KIT$231
- GENERAL BPH$223
- Coloplast TFL Drive$173
- iTIND System$146
How this compares
$149,040 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 25 | $355,349 |
| ErleadaApalutamide | 11 | $159,736 |
| GemtesaVibegron | 195 | $146,604 |
| MyrbetriqMirabegron | 148 | $100,250 |
| OrgovyxRelugolix | 20 | $53,936 |
| Tamsulosin Hcl | 1,190 | $18,434 |
| Solifenacin Succinate | 159 | $10,488 |
| Finasteride | 546 | $7,531 |
| XyostedTestosterone Enanthate | 11 | $6,586 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 198 | $3,899 |
| Trospium Chloride | 104 | $3,726 |
| Cefpodoxime Proxetil | 55 | $3,673 |
| Testosterone Cypionate | 54 | $3,003 |
| Tadalafil | 18 | $2,789 |
| Silodosin | 30 | $2,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $747 | $455,599173 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $798 | $200,541215 claims |
| Johnson & JohnsonErleada | $1,099 | $159,73611 claims |
| Antares Pharma, Inc.Xyosted | $607 | $6,58611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.
Other urology in Houston
- Zvi SchiffmanHouston$17.8M
- Jose KaramHouston$5.7M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
- Brian ChapinHouston$1.1M
- Arun RaiHouston$1M
- Ashish KamatHouston$957K
- Donald GriffithHouston$732K
- Robert CornellHouston$695K
- John DavisHouston$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.